<?xml version="1.0" encoding="UTF-8"?>
<p id="p0160">This particular drug is an adenosine nucleotide analog, which was used in treatments against Ebola, SARS-CoV and MERS-CoV. It is a promising and potential drug which causes premature termination by entering the nascent viral RNA (
 <xref rid="bb0815" ref-type="bibr">Warren et al., 2016</xref>). Currently, it is undergoing clinical trials for Ebola treatment (
 <xref rid="bb0565" ref-type="bibr">Mulangu et al., 2019</xref>). Another recent study has shown that Remidesivir scored 0.77 μM at half maximal concentration against COVID-19 and blocked viral infection (
 <xref rid="bb0800" ref-type="bibr">Wang et al., 2020a</xref>, 
 <xref rid="bb0805" ref-type="bibr">Wang et al., 2020b</xref>, 
 <xref rid="bb0810" ref-type="bibr">Wang et al., 2020c</xref>).
</p>
